Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HydroVax-001B WNV
- Development stage
- Phase 1
- Lead developer
- Najit Technologies
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
HydroVax-001B WNV is a second-generation hydrogen peroxide-inactivated whole virion West Nile Virus (WNV) vaccine candidate adjuvanted with aluminum hydroxide. It is designed to prevent disease resulting from infection with West Nile virus, which is primarily transmitted to humans through mosquito bites. This vaccine is a follow-up to the earlier HydroVax-001 WNV vaccine, which showed modest immunogenicity in previous clinical trials.
Beyond the preview
Go deeper on HydroVax-001B WNV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HydroVax-001B WNV.